CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 90 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00497055
NCT00497055Phase 2Completed
CompareCT.gov

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals

San Francisco Department of Public Health·interventional·Posted Jul 6, 2007·Updated Mar 24, 2014

In Brief

A Phase 2 clinical trial evaluating Aripiprazole and Placebo for Substance Abuse and HIV Infections. Completed, enrolled 90 participants across 1 site.

Detailed Summary

Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among men who have sex with men (MSM), putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study is a randomized, double-blind, placebo-controlled trial of the medication aripiprazole for methamphetamine-using individuals, including MSM, and will assess efficacy, acceptability, tolerability, safety, and adherence to study medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Abuse, HIV Infections
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2007
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.0 years ago

Interventions

Aripiprazoledrug

Placebodrug

Sugar pill manufactured to mimic Aripiprazole gel caps.